Elevated KIN17 expression has been observed in breast cancer [59], where it is associated with poor clinical outcomes, including lower overall survival, reduced relapse-free survival, decreased distant metastasis-free survival, and shorter post-progression survival [60]. This evidence concerns the gene KIN and breast cancer.